+ Watch NSPH
on My Watchlist
FDA clearance for the bacterial portion of its Verigene(R) Enteric Pathogens Nucleic Acid Test (EP).
Nanosphere stock looks like it's been wanting to take off for months but just can't get any hang time. I suspect the latest ATM with Aspire is weighing on the stock despite rosy projections of a doubling of revenue in 2014. I've been very negative about Nanosphere's prospects in the past but they have made significant progress in sales. I'll toss them a green thumb just in case they make good on the revenues they promise.
Short. Company is bleeding tons of cash and keeps issuing stock to make up for it. This thing is toast.
NSPH is very small, but they are doing the RIGHT THING with their products, and the recent increase in share price suggests that others think that they are doing THINGS RIGHT with the business. Their approved products are directed at saving the lives of very sick people. Sepsis is usually 80% fatal, but if the attending physician immediately identifies a pathogen behind sepsis along with expected resistance to specific antibiotics, treatment with best potential outcome can commence quickly. The companies products perform direct nucleic acid identification thereby directly fingering specific DNA (bacteria) now and soon probably RNA (virus) as well as conditions related to genetic contents.
Nsph has no debt and a solid audience. I firmly believe they will outperform the market
The diagnostics market is huge. Nanosphere offers quick turn diagnostics tools for providers, in the 1-2 hour range v. days with current technology. This is important since decisions can be made on the correct course of action for antibiotics. Since the resistance to antibiotics is a growing concern these diagnostic tools are becoming critical to providers as they wish to target the right antibiotic as fast as they can.
Last weeks drop in share price was an over reaction to the management changes. The sudden replacement of the CEO without any clearly articulated reasons spooked the market. With an FDA approved lab instrument and 4 currently approved tests for that instrument. The company uses the "razor and blades" revenue model. The company should be cash flow positive within 12 to 18 months and presently has sufficient cash to make that goal.
I have had NSPH in my watchlist since Dec. 2011 when it was trading for $1.50. Already up more than 100% since then this one still seems to have more upside now that FDA has approved their Verigene system, and lots of insider buying:http://seekingalpha.com/article/743181-speculative-3-stock-gets-important-fda-approval-and-has-heavy-insider-buying
Just a min after the kind BravoBevo it's good, but I prefer to be first like for ACUR...However the most difficut is to know the right time for selling...
Rapid diagnostics are going to be the next big thing.
It's good,I like it
Well positioned in an industry that is poised for a dramatic acceleration in growth as predictive medicine and molecular diagnostics begin to gain traction. Recent weakness primarily driven by shorter term concerns present a great entry point for longer term investors. While still burning cash (although moderatimg), a solid cash position (over $2 per share in net cash) provides sufficient financial flexibility. A good insider rating (recent CEO and 30% owner buys with no sells) is also encouraging.
Picked this on a whim.... looks like it's doing alright :)
Love the technology. Risks = they are thinly traded and very volatile.
This company is doing really cool things and think it would change our lives if it became the market leader in the emerging field of genetic and nano testing.
these kind of companies usually tend to work better on a long the range as it takes time to develope new items.
Interesting bio-tech company in the nano-technology field.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions